SOUTH SAN FRANCISCO, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that it will present at four upcoming scientific conferences. Details are as follows:
Keystone Symposia: Molecular Mechanisms of Angiogenesis in Development and Disease -- Vancouver, BC
AACR: Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic -- San Diego, CA
Keystone Symposia: Diabetes Mellitus, Insulin Action and Resistance -- Breckenridge, CO
About Rigel (http://www.rigel.com)
Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to file one new investigative new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
CONTACT: Raul Rodriguez of Rigel Pharmaceuticals, Inc., +1-650-624-1302,
invrel@rigel.com
Web site: http://www.rigel.com/
